Table 2 Sensitivity, specificity, and accuracy of predicting mepolizumab response using cutoffs defined by the top cytokine or ratios.
*Measures used in cutoff | Sensitivity | Specificity | Accuracy | AUC |
|---|---|---|---|---|
Baseline Eos ≥ 300 + IL-13 | 0.71 | 1.00 | 0.89 | 0.83 |
Baseline Eos ≥ 300 + IL-13/IL-25 | 0.71 | 1.00 | 0.89 | 0.83 |
Baseline Eos ≥ 300 + IL-13/TNF- ∝ | 0.71 | 1.00 | 0.89 | 0.83 |
Baseline Eos ≥ 300 + IL-13/IL-17F | 0.71 | 1.00 | 0.89 | 0.83 |
IL13/TNF- ∝ | 0.86 | 0.82 | 0.83 | 0.88 |
Max Eos ≥ 300 + IL-13/TNF- ∝ | 0.86 | 0.82 | 0.83 | 0.90 |
Max Eos ≥ 300 + IL-13/IL-1 ∝ | 0.71 | 0.91 | 0.83 | 0.88 |
Baseline Eos ≥ 150 + IL-13/IL-25 | 0.71 | 0.91 | 0.83 | 0.84 |
Baseline Eos ≥ 150 + IL-13/IL-17F | 0.71 | 0.91 | 0.83 | 0.84 |
IL13/IL1 ∝ | 0.71 | 0.91 | 0.83 | 0.84 |
Baseline Eos ≥ 300 + IL-13/IL-1 ∝ | 0.57 | 1.00 | 0.83 | 0.83 |
Max Eos ≥ 300 + IL-13 | 0.86 | 0.73 | 0.78 | 0.84 |
Baseline Eos ≥ 300 | 0.71 | 0.82 | 0.78 | 0.77 |
Max Eos ≥ 300 + IL-13/IL-25 | 0.71 | 0.82 | 0.78 | 0.88 |
Baseline Eos ≥ 150 + IL-13/TNF- ∝ | 0.71 | 0.82 | 0.78 | 0.82 |
Max Eos ≥ 300 + IL-13/IL-17F | 0.71 | 0.82 | 0.78 | 0.88 |
IL-13/IL-25 | 0.71 | 0.82 | 0.78 | 0.82 |
IL-13/IL-17F | 0.71 | 0.82 | 0.78 | 0.86 |
Baseline Eos ≥ 150 + IL-13/IL-1 ∝ | 0.57 | 0.91 | 0.78 | 0.82 |
IL-13 | 0.86 | 0.64 | 0.72 | 0.79 |
Baseline Eos ≥ 150 + IL-13 | 0.71 | 0.73 | 0.72 | 0.78 |
Baseline Eos ≥ 150 | 0.86 | 0.55 | 0.67 | 0.70 |
Max Eos ≥ 300 | 1.00 | 0.36 | 0.61 | 0.68 |
